Molecular genetics of benign tumors

Cancer Investigation

Volumn 20, Issue 3, 2002, Pages 362-372

  Hess, Jay L ^a   Kossev, Plamen ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP PROTEIN; HMGI C PROTEIN; HMGI Y PROTEIN; UNCLASSIFIED DRUG;

BENIGN TUMOR; ENDOMETRIUM TUMOR; FIBROADENOMA; GENE LOCATION; HAMARTOMA; HIBERNOMA; HISTOPATHOLOGY; HUMAN; LEIOMYOMA; LIPOMA; MESENCHYMOMA; MOLECULAR GENETICS; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HMGB1 PROTEIN; HUMANS; MESODERM; MOLECULAR BIOLOGY; NEOPLASMS;

EID: 0036246736     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120001182     Document Type: Review

References (101)

1. A minute chromosome in human chronic granulocytic leukemia
2. Chromosomal translocations in human cancer
3. Rowley giemsa staining
4. Characteristic chromosomal abnormalities in biopsies and lymphoid cell lines from patients with burkitt and non-burkitt lymphomas
5. Cytogenetic studies on African Burkitt's lymphoma cell lines; t(8;14), t(2;8) and t(8;22) translocations
6. The molecular genetics of non-Hodgkin's lymphomas
7. Chromosome studies in the non-Hodgkin's lymphomas: The role of the 14;18 translocation
8. Expression in non-Hodgkin's lymphomas of the bcl-2 protein associated with the t(14;18) chromosomal translocation
9. Uterine leiomyoma cytogenetics
10. Chromosome analysis of 96 uterine leiomyomas
11. Cytogenetic profile of 109 lipomas
12. Cytogenetic aberrations in 188 benign and borderline adipose tissue tumors
13. t(6;12)(q23;q13) and t(10;16)(q22;p11) in a phylloides tumor of the breast
14. Two human breast tumors with translocations involving 12q13-15 as the sole cytogenetic abnormality
15. Chromosome abnormalities in breast fibroadenomas
16. Cytogenetic and molecular observations in human and experimental salivary gland tumors
17. Cytogenetic subtyping of 220 salivary gland pleomorphic adenomas: Correlation to occurrence, histological subtype, and in vitro cellular behavior
18. Inv(12)(p11.2q13) in an endometrial polyp
19. Endometrial polyp: Another benign tumor characterized by 12q13-q15 changes
20. Chromosomal rearrangements in chondromatous tumors
21. Clonal karyotypic aberrations in enchondroma
22. Rearrangement of 12q14-15 in pulmonary chondroid hamartoma
23. Cytogenetic and molecular analysis of aggressive angiomyxoma
24. The cytogenetic and molecular characterization of benign and malignant soft tissue tumors
25. Fusion genes in solid tumors
26. High mobility group chromosomal proteins: Architectural components that facilitate chromatin function
27. Chromosomal translocations in benign tumors: The HMGI proteins
28. Organization, inducible-expression and chromosome localization of the human HMGI(Y) non-histone protein gene
29. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes
30. Expression and cDNA cloning of human HMGI-C phosphoprotein
31. The A-T-DNA-Binding domain of mammalian high mobility group I chromosomal proteins: A novel peptide motif for recognizing DNA structure
32. From the chromosomal loops to the classic bands of metaphase chromosomes
33. Metaphase chromosome structure: Bands arise from a differential folding path of the highly AT-rich scaffold
34. A glimpse at chromosomal order
35. cdc2: In vivo veritas
36. Phosphorylation of the DNA-binding domain of nonhistone high-mobility group I protein by cdc2 kinase: Reduction of binding affinity
37. Phosphorylation by cdc2 kinase modulates DNA binding activity of high mobility group I nonhistone chromatin protein
38. cdc13 kinase
39. Chromatin changes during the cell cycle
40. The high mobility group protein HMGI(Y) is required for NF-κB-dependent virus induction of the human IFN[3 IFNP gene
41. The role of HMGI(Y) in the assembly and function of the β-interferon enhanceosome
42. The high mobility group protein hmi(y) is an essential structural component of a virus inducible enhancer complex
43. Virus inductionn of human ifnβ gene expression requires the assembly of an enhanceosome
44. Acetylation by HMGI(Y) by CBP turns off INFβ expression by disrupting the enhanceosome
45. Functional roles of the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DRA gene expression
46. An IL-2 response element in the human IL-2 receptor α chain is a composite element that binds stat 5, Elf-1, HMGI(Y), and a GATA family protein
47. Involvement of a high-mobility group protein in the transcriptional activity of the herpes simplex virus latency-active promoter 2
48. The Non-histone chromosomal protein HMG-I(Y) contributes to the immunoglobulin heavy chain germ-line epsilon RNA promoter
49. Multiple closely-linked NFAT/Octamer and HMG-I(Y) binding sites are a part of the interleukin-4 promoter
50. Sequence specific binding of HMG-I(Y) to the proximal promoters of the GP91-PHOX gene
51. Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene
52. HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemia cells
53. Mini-Mouse: Disruption of the pygmy locus in a transgenic insertional mutant
54. Mutation responsible for mouse pygmy phenotype in the developmentally regulated factor HMGI-C
55. The chromosomal high mobility group protein HMG-I(Y): Complete murine cDNA sequence, and tissue expression
56. Expression of mRNAs encoding mammalian chromosomal proteins HMG-I and HMG-Y during cellular proliferation
57. On the presence of the chromosomal proteins HMG-I and HMG-Y in rat organs
58. Analysis of HMGI nuclear proteins in mouse neoplastic cells induced by different procedures
59. Analysis of multiple forms of the HMGI proteins in rodent and human cells: Identification of the third protein, HMGI-C in human cells
60. High-mobility-group-proteins and histone H1 subtypes expression in normal and tumor tissues of mouse
61. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by co-transfection with c-myc and polyoma middle T genes
62. Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene
63. Fractionation and identification of metaphase-specific posphorylated forms of high-mobility-group proteins
64. Differential regulation of a multipromoter gene
65. Expression of mRNAs encoding mammalian chromosomal proteins HMG-I and HMG-Y during cellular proliferation
66. Identification of high mobility group protein I(Y) as potential marker for prostate cancer by differential hybridization analysis
67. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization
68. Elevated high mobility group-I(Y) expression is associated with progressive transformation of mouse mammary epithelial cells
69. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells
70. A 6-Mb yeast artificial chromosome contig and long-range physical map encompassing the region on chromosome 12q15 frequently rearranged in a variety of benign solid tumors
71. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains
72. Recurrent rearrangements in the high mobility group protein gene, HMGI-C in benign mesenchymal tumors
73. Zyxin and cCRP: Two interactive LIM domain proteins associated with the cytoskeleton
74. Rabbitts development
75. Correlation between clinicopathologic features and karyotype in lipomatous tumors: A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group
76. Description of a novel fusion transcript between HMGI-C, a gene encoding for a member of the high mobility group proteins, and the mitochondrial aldehyde dehydrogenase gene
77. Amplification of a rearranged form of the high mobility group protein gene HMGIC in OSA-CI osteosarcoma cells
78. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts
79. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis
80. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas
81. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical limpomatous tumors: Immunohistochemical reactivity correlates with karyotypic alterations
82. Amplification and expression of the HMGIC gene in a benign endometrial polyp
83. HMG-I(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma
84. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas. Endometrial polyps and uterine leiomyomas and is compatible with rearrangements of the HMGI-C and HMGI(Y) genes
85. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors
86. Lineage restricted clonality in biphasic solid tumors
87. Clonal rearrangement of band 6p21 in mesenchymal component of pulmonary chondroid hamartoma
88. Clonal 6p21 rearrangement is restricted to the mesenchymal components of an endometrial polyp
89. Preferential expressiona of HMGI-C isoforms lacking the acidic carboxyl terminal in human leukemia
90. The t(4; 11) translocation of human acute leukemias fuses the ALL-gene, related to drosophila trithorax, to the AF-4 gene
91. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias
92. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias
93. Acute mixed lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product
94. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed lineage leukemia (MLL) gene
95. The mixed lineage leukemia gene (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA
96. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENI, and the DNA binding motifs of HRX
97. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleomorphic adenomas with t(3;8)(p21;q12) translocations
98. Pleomorphic adenoma gene - Is expressed in cultured benign and malignant salivary gland turaor cells
99. The recurrent translocation t(5:8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under the control of the LIFR promoter
100. Conserved mechanism of PLAG1 activation in saliary gland tumors with and without chromosome 8q12 abnormalities: Identification of SII as a new fusion partner gene
101. PLAG1, the main translocation partne in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II